We are live on ! Find out more

585 hedge funds and large institutions have $10.7B invested in Sanofi in 2021 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 232 increasing their positions, 157 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more call options, than puts

Call options by funds: $39M | Put options by funds: $17.6M

48% more repeat investments, than reductions

Existing positions increased: 232 | Existing positions reduced: 157

42% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 43

40% more funds holding in top 10

Funds holding in top 10: 57 (+2)

9% more capital invested

Capital invested by funds: $9.77B → $10.7B (+$917M)

2% more funds holding

Funds holding: 572585 (+13)

0.4% more ownership

Funds ownership: 15.66%16.06% (+0.4%)

Holders
585
Holders Change
+13
Holders Change %
+2.27%
% of All Funds
10.18%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.12%
New
61
Increased
232
Reduced
157
Closed
43
Calls
$39M
Puts
$17.6M
Net Calls
+$21.4M
Net Calls Change
-$5.11M
Name Holding Trade Value Shares
Change
Change in
Stake
Dodge & Cox
1
Dodge & Cox
California
$3.7B +$63.6M +1,219,164 +2%
Fisher Asset Management
2
Fisher Asset Management
Washington
$942M -$12.9M -247,533 -1%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$870M +$105M +2,005,559 +14%
BlackRock
4
BlackRock
New York
$766M -$29.2M -559,939 -4%
Bank of America
5
Bank of America
North Carolina
$523M +$43.5M +833,701 +9%
Invesco
6
Invesco
Georgia
$286M -$5.56M -106,456 -2%
Hotchkis & Wiley Capital Management
7
Hotchkis & Wiley Capital Management
California
$268M -$19.7M -378,098 -7%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$231M -$85.7K -1,642 -0%
Lazard Asset Management
9
Lazard Asset Management
New York
$171M +$10.6M +203,040 +7%
PPA
10
Parametric Portfolio Associates
Washington
$159M +$11.6M +222,158 +8%
Macquarie Group
11
Macquarie Group
Australia
$148M -$13.3M -254,325 -8%
CCM
12
Camber Capital Management
Massachusetts
$118M +$117M +2,250,000 New
Northern Trust
13
Northern Trust
Illinois
$111M -$16.5M -316,709 -13%
Morgan Stanley
14
Morgan Stanley
New York
$108M -$27.2M -521,015 -20%
Goldman Sachs
15
Goldman Sachs
New York
$95M +$14.3M +273,128 +18%
Wells Fargo
16
Wells Fargo
California
$84.4M -$4.15M -79,448 -5%
HCM
17
Hamlin Capital Management
New York
$82.5M +$598K +11,460 +0.7%
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
$81.8M +$3.04M +58,214 +4%
EIC
19
Equity Investment Corp
Georgia
$80.7M +$32.4M +620,942 +68%
Point72 Asset Management
20
Point72 Asset Management
Connecticut
$74.2M +$18.4M +352,229 +33%
Primecap Management
21
Primecap Management
California
$72.7M -$651K -12,480 -0.9%
MIP
22
Mondrian Investment Partners
United Kingdom
$69.1M
Natixis Advisors
23
Natixis Advisors
Massachusetts
$63.2M +$3.01M +57,729 +5%
First Trust Advisors
24
First Trust Advisors
Illinois
$59M -$3.09M -59,261 -5%
UBS Group
25
UBS Group
Switzerland
$55.1M +$11M +211,451 +25%

SNY Hedge Fund Activity: Q2 2021 in Review

585 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q2 2021, worth a combined $10.7B — up 9.4% from $9.77B a quarter earlier.

Buyers outnumbered sellers: 61 funds opened new SNY positions and 43 closed out — a net gain of 18 holders — while 232 added to existing stakes and 157 trimmed.

The largest buyer was Camber Capital Management, opening a new position worth an estimated $117M. The largest seller was Arrowstreet Capital, cutting an estimated $47.7M.

  • 585 institutional investors held Sanofi (SNY) as of Q2 2021, up from 572 in Q1 2021.
  • Funds reported $10.7B of Sanofi stock for Q2 2021, up 9.4% quarter-over-quarter.
  • 61 funds opened new Sanofi positions in Q2 2021 and 43 closed out, a net change of +18 holders.
  • The largest Sanofi buyer in Q2 2021 was Camber Capital Management, an estimated $117M added.
  • The largest Sanofi seller in Q2 2021 was Arrowstreet Capital, an estimated $47.7M sold.

Based on aggregated 13F filings for Q2 2021.